GSK3862995B

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

BronchiectasisPulmonary Disease, Chronic Obstructive

Phase 1

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

Active, not recruitingNCT06154837

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2023-11-27End: 2026-12-17Updated: 2026-05-29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

CompletedNCT06979518

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2025-05-20End: 2026-04-22Updated: 2026-06-11

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants

RecruitingNCT07789899

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2026-08-18End: 2027-09-07Target: 24Updated: 2026-09-01

Phase 2

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

RecruitingNCT07201051

GlaxoSmithKlineBronchiectasis

Start: 2025-10-30End: 2027-12-10Target: 363Updated: 2026-08-12